NASDAQ:SRTS • US81728J1097
The current stock price of SRTS is 4.41 USD. Today SRTS is down by -4.34%. In the past month the price decreased by -14.86%. In the past year, price decreased by -4.13%.
ChartMill assigns a technical rating of 4 / 10 to SRTS. When comparing the yearly performance of all stocks, SRTS turns out to be only a medium performer in the overall market: it outperformed 50.17% of all stocks.
ChartMill assigns a fundamental rating of 4 / 10 to SRTS. No worries on liquidiy or solvency for SRTS as it has an excellent financial health rating, but there are worries on the profitability.
On February 12, 2026 SRTS reported an EPS of -0.19 and a revenue of 4.94M. The company missed EPS expectations (-166.11% surprise) and missed revenue expectations (-41.98% surprise).
9 analysts have analysed SRTS and the average price target is 6.8 USD. This implies a price increase of 54.2% is expected in the next year compared to the current price of 4.41.
For the next year, analysts expect an EPS growth of 86.98% and a revenue growth 15.07% for SRTS
Over the last trailing twelve months SRTS reported a non-GAAP Earnings per Share(EPS) of -0.47. The EPS decreased by -217.5% compared to the year before.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PM (TTM) | N/A | ||
| ROA | -5.16% | ||
| ROE | -5.87% | ||
| Debt/Equity | 0 |
| Symbol | Company Name | Technical Rating | Fundamental Rating | FPE | Market Cap |
|---|---|---|---|---|---|
| ABT | ABBOTT LABORATORIES | 19.7 | 196.666B | ||
| ISRG | INTUITIVE SURGICAL INC | 49.03 | 177.984B | ||
| SYK | STRYKER CORP | 25.26 | 146.042B | ||
| BSX | BOSTON SCIENTIFIC CORP | 20.62 | 107.089B | ||
| IDXX | IDEXX LABORATORIES INC | 43.78 | 51.799B | ||
| EW | EDWARDS LIFESCIENCES CORP | 28.66 | 49.453B | ||
| BDX | BECTON DICKINSON AND CO | 10.88 | 48.859B | ||
| RMD | RESMED INC | 21.1 | 37.738B | ||
| GEHC | GE HEALTHCARE TECHNOLOGY | 15.73 | 36.013B | ||
| DXCM | DEXCOM INC | 28.87 | 28.433B | ||
| ZBH | ZIMMER BIOMET HOLDINGS INC | 11.18 | 18.976B | ||
| PODD | INSULET CORP | 38.31 | 17.087B | ||
| HOLX | HOLOGIC INC | 15.04 | 16.893B |
View all stocks in the Health Care Equipment Industry | View all stocks in the Health Care Sector | View all stocks on the Nasdaq Exchange | Find stocks with similar TA and Setup ratings on the USA exchanges | Find stocks with similar Fundamental rating on the USA exchanges | Find the competitors with the best technical ratings on the USA exchanges | Find the competitors with the best fundamentals on the USA exchanges | Find the competitors with the best valuation on the USA exchanges | Find the competitors with the best dividend on the USA exchanges | Find the competitors with the best analyst ratings on the USA exchanges
Sensus Healthcare, Inc. is a medical device company, which engages in the provision of treatment for both oncological and non-oncological skin conditions. The company is headquartered in Boca Raton, Florida. The company went IPO on 2016-06-03. The Company, leveraging its superficial radiotherapy (SRT and IG-SRT) technology, provides healthcare providers with a patient-centric treatment platform. Its products and services include SRT-100, SRT-100 Vision, SRT-100+, Sentinel service program and others. The SRT-100 is a photon x-ray low energy SRT system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides customers with additional options compared to the SRT-100 base model. These additional options allow for dedicated treatment planning and full treatment progression documentation in a patient’s record. The SRT-100+ offers all the same features as the SRT-100, with the addition of remote diagnostics and other features.
SENSUS HEALTHCARE INC
851 Broken Sound Pkwy NW Ste 215
Boca Raton FLORIDA 33487 US
CEO: Joseph C. Sardano
Employees: 54
Phone: 13023513367
Sensus Healthcare, Inc. is a medical device company, which engages in the provision of treatment for both oncological and non-oncological skin conditions. The company is headquartered in Boca Raton, Florida. The company went IPO on 2016-06-03. The Company, leveraging its superficial radiotherapy (SRT and IG-SRT) technology, provides healthcare providers with a patient-centric treatment platform. Its products and services include SRT-100, SRT-100 Vision, SRT-100+, Sentinel service program and others. The SRT-100 is a photon x-ray low energy SRT system that provides patients an alternative to surgery for treating non-melanoma skin cancers, including basal cell and squamous cell skin cancers and other skin conditions such as keloids. The SRT-100 Vision provides customers with additional options compared to the SRT-100 base model. These additional options allow for dedicated treatment planning and full treatment progression documentation in a patient’s record. The SRT-100+ offers all the same features as the SRT-100, with the addition of remote diagnostics and other features.
The current stock price of SRTS is 4.41 USD. The price decreased by -4.34% in the last trading session.
SRTS does not pay a dividend.
SRTS has a ChartMill Technical rating of 4 out of 10 and a ChartMill Fundamental rating of 4 out of 10.
SENSUS HEALTHCARE INC (SRTS) does not have a PE ratio as the earnings reported over the last twelve months were negative (-0.47).
SENSUS HEALTHCARE INC (SRTS) currently has 54 employees.
SENSUS HEALTHCARE INC (SRTS) has a market capitalization of 72.46M USD. This makes SRTS a Micro Cap stock.